



LTR Pharma to Present SPONTAN® Clinical Data at Major Urological Conference

28 February 2025

Highlights:

- LTR Pharma to Present SPONTAN® Clinical Data at Major Urological Conference
- Data demonstrates SPONTAN achieves 470% faster absorption than current ED tablets
- Presentation validates SPONTAN's potential to disrupt the global ED market
- Conference strengthens SPONTAN's profile with key prescribers

LTR Pharma Limited (ASX:LTR) ("LTR Pharma", "the Company") has today announced that Professor Eric Chung, Chief Scientific and Clinical Advisor, will present SPONTAN's pivotal clinical trial data at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting in Perth from 1 to 4 March 2025.

Professor Chung's podium presentation will showcase SPONTAN's breakthrough clinical results, demonstrating its significant advantages over existing erectile dysfunction (ED) treatments. The data shows SPONTAN achieved a mean time to maximum plasma concentration of 12 minutes compared to 56 minutes for oral tablets - marking a 470% faster absorption rate. Importantly, these results were achieved using half the drug dose of oral tablets while maintaining comparable bioavailability and a favourable safety profile.

LTR Pharma Chief Scientific and Clinical Advisor, Professor Eric Chung, said: *"The clinical data underpinning SPONTAN's development demonstrates its potential to address significant unmet needs in erectile dysfunction treatment. The rapid onset of action, coupled with excellent bioavailability and safety profile, offers patients a more spontaneous therapeutic option. This has been further validated through real-world patient feedback under the TGA's Special Access Scheme and Authorised Prescriber pathways. I look forward to sharing these compelling results with my colleagues at USANZ."*

LTR Pharma will also be exhibiting at the conference alongside Restorative Health Clinic, one of the first healthcare providers to prescribe SPONTAN under the TGA's Special Access Scheme.

Speaker Profile, LTR Pharma Chief Scientific and Clinical Advisor, Professor Eric Chung

Professor Eric Chung is the leading international Men's Health expert and consultant urological surgeon at the AndroUrology Centre for Male Sexual, Urinary, and Reproductive Excellence. He holds professorial academic appointments at the University of Queensland in Brisbane and Macquarie University Hospital in Sydney. He is the President-elect of the International Society of Sexual Medicine (ISSM), Past Chair of the Andrology section for the Urological Society of Australia and New Zealand (USANZ), and Past Secretary-General of the Asia Pacific Society of Sexual Medicine (APSSM).

- ENDS -

This announcement has been approved by the Board of Directors.



LTR Pharma

For further information please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma's lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.